San Diego-based mostly Viking Therapeutics marked itself as a serious competitor in the weight loss drug market in February immediately after revealing promising data from the mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when provided like a weekly injection and in March the company